Add to a list

Inactive Instrument

Dechra Pharmaceuticals PLC Stock OTC Markets

DCHPF

GB0009633180

OTC Markets Traded

Valuation: Dechra Pharmaceuticals PLC

Market Cap	4.4B 5.86B 5.15B 4.79B 8.26B 567B 8.41B 57.25B 22.33B 277B 22B 21.52B 960B	P/E 2022	64.8x	P/E 2023	-150x
Enterprise Value	4.83B 6.43B 5.66B 5.26B 9.06B 623B 9.23B 62.85B 24.51B 304B 24.15B 23.63B 1,054B	EV / Sales 2022	5.8x	EV / Sales 2023	6.08x
Free-Float	-	Yield 2022	1.3%	Yield 2023	0.34%

* Estimated data More valuation ratios

Latest news : Dechra Pharmaceuticals PLC

06-25	Dechra Opens New Global Headquarters in Boston and Invests $60,000 in Local Community Partnerships	CI
05-19	Dechra Veterinary Products LLC Announces FDA Approval Of Cosacthen Cosyntropin Injection For Canine Patients	CI
03-31	Dechra Pharmaceuticals Limited Announces Termination of Jonathan David Lang as Director, Effective March 31, 2026	CI
03-11	Dechra Announces Consolidation Of Its Existing U.S. Office Footprint In Kansas City, Kan. And Portland, Maine	CI
03-11	Dechra Announces Plans to Relocate Its Global Headquarters from Northwich, England, to Boston, Massachusetts	CI
13/10/25	Intervacc Extends Equine Strangles Vaccine Distribution Deal with Dechra Pharmaceuticals	MT
13/10/25	Intervacc and Dechra Extend Distribution Agreement for Intervacc's Equine Strangle Vaccine Strangvac by Two Years	CI
03/09/25	Dechra Pharmaceuticals Limited completed the acquisition of Invetx, Inc. from a group of shareholders for approximately $530 million	CI
18/08/25	Dechra Pharmaceuticals PLC Launches Strangvac in Spain, Portugal and Slovenia	CI
17/06/25	Vaxxinova GmbH acquired Poultry Vaccines Business of Dechra Pharmaceuticals Limited.	CI
05/05/25	Dechra Pharmaceuticals to Launch Intervacc's Horse Vaccine in Finland	MT
05/05/25	Dechra Pharmaceuticals plc Launches Strangvac in Finland	CI
18/07/24	Dechra Pharmaceuticals Limited agreed to acquire Invetx, Inc. from a group of shareholders for $520 million.	CI

More news

Analysts' recommendations: Dechra Pharmaceuticals PLC

27/06/23	Stifel Downgrades Dechra Pharmaceuticals to Hold from Buy, Lowers PT	MT
27/06/23	Analyst recommendations: Alphabet, Amgen, GSK, Moderna, Smiths Group...
27/06/23	UBS cuts BT'; HSBC starts Smiths with 'hold'	AN
07/03/23	Davy ups Purplebricks; JPMorgan cuts Clarkson	AN
12/01/23	UBS cuts Beazley; Berenberg likes Rio and BHP	AN

More recommendations

Press Releases: Dechra Pharmaceuticals PLC

27/12/23	Form 8.5 (EPT/RI) - Dechra Pharmaceuticals plc	AQ
30/10/23	Dechra Pharmaceuticals : 30 October 2023 Annual Report 2023 (Online)	PU
17/10/23	Dechra Pharmaceuticals : 17 October 2023 Annual Report 2023 ESEF XHTML	PU
17/10/23	Dechra Pharmaceuticals : 17 October 2023 Annual Report 2023	PU
07/09/23	Form 8.3 - Dechra Pharmaceuticals plc	AQ

More press releases

News in other languages: Dechra Pharmaceuticals PLC

12/01/24	BOLETÍN MATINAL : 12 de enero de 2024
13/12/23	Pharma und Gesundheit: weitere Konsolidierung
12/12/23	Farma en gezondheid: consolidatie gaat door
11/12/23	Farmaceutica e salute: continua il consolidamento
11/12/23	Farmacia y salud: La consolidación continúa

More news

Managers and Directors: Dechra Pharmaceuticals PLC

Manager	Title	Age	Since
Jesper Nordengaard CEO	Chief Executive Officer	-	10/06/2024
Paul Sandland DFI	Director of Finance/CFO	46	03/04/2019
Jamie Adams CTO	Chief Tech/Sci/R&D Officer	-	-

Director	Title	Age	Since
Paul Sandland BRD	Director/Board Member	46	30/10/2019
Lawson Macartney BRD	Director/Board Member	68	01/12/2016
Lisa Bright BRD	Director/Board Member	59	01/02/2019

More insiders

Dechra Pharmaceuticals PLC specializes in the manufacturing and marketing of veterinary pharmaceutical products. Net sales break down by family of products as follows: - companion animal products (74.6%); - food producing animal products (11.5%); - equine health products (7.3%); - animal feeds (5.1%); - other (1.5%): products manufactured by third parties. Net sales are distributed geographically as follows: the United Kingdom (8.5%), Germany (9.2%), Europe (31.2%), the United States (37.9%) and other (13.2%).

Employees

Sector

More about the company

	2022	2023
Net sales	682M 907M 798M 741M 1.28B 87.86B 1.3B 8.86B 3.46B 42.86B 3.41B 3.33B 149B	762M 1.01B 891M 828M 1.43B 98.14B 1.45B 9.9B 3.86B 47.87B 3.8B 3.72B 166B
Net income	58.2M 77.45M 68.12M 63.28M 109M 7.5B 111M 757M 295M 3.66B 291M 284M 12.69B	-27.9M -37.13M -32.65M -30.34M -52.32M -3.6B -53.26M -363M -141M -1.75B -139M -136M -6.08B
Net Debt	208M 277M 244M 226M 390M 26.83B 397M 2.71B 1.06B 13.09B 1.04B 1.02B 45.4B	430M 572M 503M 468M 807M 55.43B 821M 5.59B 2.18B 27.04B 2.15B 2.1B 93.79B

Dechra Pharmaceuticals PLC Stock OTC Markets

Stocks